Pediatrix Medical Group demonstrated a resilient financial performance in the second quarter of 2026, with revenue expanding by 4%. This growth was primarily fueled by strategic acquisitions and effective pricing strategies, which compensated for a slight reduction in patient activity. The company's management emphasized the positive impact of enhanced revenue cycle management (RCM) and a beneficial shift in payer demographics, alongside an increase in patient acuity. Amid these developments, Pediatrix maintained its commitment to shareholder value through ongoing share repurchases and reiterated its Adjusted EBITDA forecast for the entire year 2026. The strategic direction involves a significant push into integrated digital and physical care models, particularly in women's and children's health sectors.
During the earnings call held on August 4, 2026, CEO Mark Ordan and CFO Kasandra Rossi presented the quarter's highlights. Net revenue reached $487.8 million, marking a 4% increase year-over-year. This was largely attributed to a 2.1% growth from non-same-unit activities, complemented by a 1.9% increase in same-unit revenue. Adjusted EBITDA improved to $76.4 million from $73.2 million in the previous year, while adjusted earnings per share rose to $0.63, up from $0.53 in Q2 2025. Net income stood at $39.8 million, or $0.49 per diluted share. Despite a 2.1% decrease in same-unit patient volume, notably a 3.2% decline in Neonatal Intensive Care Unit (NICU) days, the company's financial metrics were bolstered by a 4% increase in same-unit pricing. This pricing strength derived from better RCM collections, a more favorable commercial payer mix, and higher patient acuity.
Key operational costs also saw adjustments. Practice salaries and benefits increased to $336.1 million, reflecting higher clinical salaries and malpractice expenses, though the salary growth rate remained stable at 3% to 3.5%. General and administrative expenses climbed to $61.3 million, largely due to executive transition costs. Furthermore, transformational and restructuring expenses rose to $8.5 million, driven by RCM transition initiatives. The company's financial health was underpinned by $288.9 million in cash and equivalents, with net debt at $295.3 million, resulting in a leverage ratio just over 1.0x. Pediatrix also aggressively repurchased nearly 2 million shares in the quarter, contributing to a total of 7 million shares bought back since August 2025, reducing weighted average shares outstanding to 81.4 million.
Management underscored its strategic initiatives, particularly the expansion of telemedicine and obstetric hospitalist services. CEO Ordan emphasized the effectiveness of integrating telemedicine with physical patient visits, envisioning a 'telehybrid medicine' model. This approach is designed to extend care into 'care deserts' and enhance services in women's and children's healthcare, covering areas like retinopathy, neurology, and infectious disease. CFO Rossi noted that RCM collections, payer mix, and acuity collectively accounted for approximately 95% of the quarter's pricing improvements, although she anticipates the RCM tailwind to moderate in the latter half of 2026. The company also confirmed the completion of its practice portfolio management plans, with all dispositions finalized. Pediatrix continues to seek growth opportunities through potential joint ventures and partnerships, leveraging its strong balance sheet.
In summary, Pediatrix Medical Group's second quarter of 2026 demonstrated robust financial gains, buoyed by strategic acquisitions and an optimized revenue collection process. The firm successfully managed to offset reduced patient volumes through improved pricing and an advantageous mix of commercial payers. With a clear vision for expanding its footprint in women's and children's health through innovative telehybrid medicine models and ongoing share repurchases, Pediatrix is positioning itself for sustained growth and operational efficiency, confidently reaffirming its annual financial projections.
